LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.

    Lindley, Anouk / Prager, Gerald / Bitzer, Michael / Burn, Timothy C / Lihou, Christine F / Croft, Elisabeth

    Cancer research and treatment

    2024  

    Abstract: Purpose: Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access Program (EAP) allows ... ...

    Abstract Purpose: Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access Program (EAP) allows physicians in regions where pemigatinib is not commercially available to request pemigatinib for patients with locally advanced or metastatic CCA who, in the physician's opinion, could benefit from pemigatinib treatment.
    Materials and methods: Eighty-nine patients from Europe, North America, and Israel were treated from January 2020 through September 2021.
    Results: Patients had FGFR gene fusions (68.5%), rearrangements (12.4%), translocations (5.6%), amplifications (2.2%), and other alterations (11.2%). Median duration of treatment in the EAP was 4.0 months (range, 0.1-13.6). The most frequently reported adverse event (AE) was hyperphosphatemia (22.5%); the most common serious AE was cholangitis (3.4%). Treatment discontinuation was associated with reports of AEs for seven patients (7.9%). AEs associated with pemigatinib were consistent with those observed in clinical trials.
    Conclusion: Efficacy was not assessed in this EAP. However, some patients remained on treatment for up to a year, suggesting that they observed a benefit from treatment. Patients with CCA should undergo molecular testing to identify those who could benefit from targeted treatments such as pemigatinib.
    Language English
    Publishing date 2024-02-07
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2133613-1
    ISSN 2005-9256 ; 1598-2998
    ISSN (online) 2005-9256
    ISSN 1598-2998
    DOI 10.4143/crt.2023.1197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7043: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Progression-Free Survival in Patients With Cholangiocarcinoma With or Without

    Bibeau, Kristen / Féliz, Luis / Lihou, Christine F / Ren, Haobo / Abou-Alfa, Ghassan K

    JCO precision oncology

    2022  Volume 6, Page(s) e2100414

    Abstract: Purpose: Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second- ... ...

    Abstract Purpose: Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced/metastatic CCA before enrollment in the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376).
    Patients and methods: Patients with locally advanced or metastatic CCA with
    Results: Among patients with
    Conclusion: In patients with CCA and
    MeSH term(s) Bile Duct Neoplasms/drug therapy ; Bile Ducts, Intrahepatic/pathology ; Cholangiocarcinoma/drug therapy ; Humans ; Progression-Free Survival ; Prospective Studies ; Receptor, Fibroblast Growth Factor, Type 2/genetics
    Chemical Substances Receptor, Fibroblast Growth Factor, Type 2 (EC 2.7.10.1)
    Language English
    Publishing date 2022-05-11
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.21.00414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with

    Bekaii-Saab, Tanios S / Valle, Juan W / Van Cutsem, Eric / Rimassa, Lorenza / Furuse, Junji / Ioka, Tatsuya / Melisi, Davide / Macarulla, Teresa / Bridgewater, John / Wasan, Harpreet / Borad, Mitesh J / Abou-Alfa, Ghassan K / Jiang, Ping / Lihou, Christine F / Zhen, Huiling / Asatiani, Ekaterine / Féliz, Luis / Vogel, Arndt

    Future oncology (London, England)

    2020  Volume 16, Issue 30, Page(s) 2385–2399

    Abstract: FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and ... ...

    Abstract FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with previously treated locally advanced/metastatic CCA harboring
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bile Duct Neoplasms/diagnosis ; Bile Duct Neoplasms/drug therapy ; Bile Duct Neoplasms/genetics ; Bile Duct Neoplasms/mortality ; Biomarkers, Tumor ; Cholangiocarcinoma/diagnosis ; Cholangiocarcinoma/drug therapy ; Cholangiocarcinoma/genetics ; Cholangiocarcinoma/mortality ; Cisplatin/administration & dosage ; Clinical Protocols ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Gene Rearrangement ; Humans ; Male ; Molecular Targeted Therapy ; Morpholines/administration & dosage ; Morpholines/adverse effects ; Morpholines/therapeutic use ; Mutation ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Pyrroles/administration & dosage ; Pyrroles/adverse effects ; Pyrroles/therapeutic use ; Receptor, Fibroblast Growth Factor, Type 2/genetics ; Research Design ; Treatment Outcome ; Gemcitabine
    Chemical Substances Biomarkers, Tumor ; Morpholines ; Pyrimidines ; Pyrroles ; Deoxycytidine (0W860991D6) ; FGFR2 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 2 (EC 2.7.10.1) ; Cisplatin (Q20Q21Q62J) ; pemigatinib (Y6BX7BL23K) ; Gemcitabine
    Language English
    Publishing date 2020-07-17
    Publishing country England
    Document type Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2020-0429
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6478: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

    Abou-Alfa, Ghassan K / Sahai, Vaibhav / Hollebecque, Antoine / Vaccaro, Gina / Melisi, Davide / Al-Rajabi, Raed / Paulson, Andrew S / Borad, Mitesh J / Gallinson, David / Murphy, Adrian G / Oh, Do-Youn / Dotan, Efrat / Catenacci, Daniel V / Van Cutsem, Eric / Ji, Tao / Lihou, Christine F / Zhen, Huiling / Féliz, Luis / Vogel, Arndt

    The Lancet. Oncology

    2020  Volume 21, Issue 5, Page(s) 671–684

    Abstract: Background: Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour ... ...

    Abstract Background: Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements.
    Methods: In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations. All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 weeks on, 1 week off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision. The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib. This study is registered with ClinicalTrials.gov, NCT02924376, and enrolment is completed.
    Findings: Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetermined FGF/FGFR alteration. The median follow-up was 17·8 months (IQR 11·6-21·3). 38 (35·5% [95% CI 26·5-45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses). Overall, hyperphosphataemia was the most common all-grade adverse event irrespective of cause (88 [60%] of 146 patients). 93 (64%) patients had a grade 3 or worse adverse event (irrespective of cause); the most frequent were hypophosphataemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatraemia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]). Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related.
    Interpretation: These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.
    Funding: Incyte Corporation.
    MeSH term(s) Adult ; Aged ; Cholangiocarcinoma/drug therapy ; Cholangiocarcinoma/genetics ; Cholangiocarcinoma/pathology ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Fibroblast Growth Factors/genetics ; Humans ; Male ; Middle Aged ; Morpholines/administration & dosage ; Morpholines/adverse effects ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Oncogene Proteins, Fusion/genetics ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrroles/administration & dosage ; Pyrroles/adverse effects ; Receptor, Fibroblast Growth Factor, Type 2/genetics ; Receptors, Fibroblast Growth Factor/genetics
    Chemical Substances Morpholines ; Oncogene Proteins, Fusion ; Protein Kinase Inhibitors ; Pyrimidines ; Pyrroles ; Receptors, Fibroblast Growth Factor ; Fibroblast Growth Factors (62031-54-3) ; FGFR2 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 2 (EC 2.7.10.1) ; pemigatinib (Y6BX7BL23K)
    Language English
    Publishing date 2020-03-20
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(20)30109-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top